TGFB1 and neoplasm: While SMAD signaling mainly accounts for the tumor-suppressive functions of TGF-β, the non-SMAD pathways predominate during later stages of tumor development when the SMAD pathway is often inactivated, e.g., by mutations in DPC4, to mediate the tumor-promoting functions of TGF-β.